Compare Coursera Inc (COUR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Mesoblast Limited — how do they compare? Coursera Inc trades at $5.65 (market cap $1.52B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | MESO | |
|---|---|---|
Market Cap | $1.52B | $2.16B |
Sector | Consumer Staples | Technology |
52-Week High | $12.20 | $20.96 |
52-Week Low | $5.09 | $12.88 |
Enterprise Value | $778.04M | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.81, up 4.5% with bullish technical signals and strong analyst support. The company shows improving revenue growth ($757.5M in 2025, projected to $885M in 2026) but remains unprofitable with negative margins. Recent Q2 2026 earnings beat expectations with $0.17 EPS versus $0.10 estimate, while the company made a strategic $100M investment in AI education startup LearnVector.
The stock offers 32% upside to consensus price target of $7.70, supported by 53% buy ratings, but faces execution risks from persistent losses and competitive pressures in online education. Revenue growth trajectory and cost management will be critical for valuation improvement.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
